Literature DB >> 12234745

Neuromaturation of multiples.

Marilee C Allen1, Pamela K Donohue.   

Abstract

Etiology of preterm birth and degree of maturation are the primary determinants of a preterm infant's survival and complications. Multiple gestation increases the likelihood of preterm birth but its influence on rate of maturation or complications of prematurity has been controversial, primarily because of confounding variables (e.g. race, aetiology of preterm delivery, degree of prematurity and pregnancy complications). Very low birthweight preterm multiples have virtually the same rates of neonatal mortality, complications and neuromaturation as preterm singletons of the same gestational age. There is no advantage of delivering twins or higher order multiples before 30 weeks gestation, unless a fetus decompensates in utero. Survival improves for near term intermediate-size preterm multiples while intrauterine growth decelerates and placental and fetal neuromaturation accelerate. These data and the high fetal death rate at term support delivery of multiples as soon as there is fetal lung maturity, and consideration of elective delivery of twins at 35-38 weeks gestation and triplets at 33-35 weeks gestation.

Entities:  

Mesh:

Year:  2002        PMID: 12234745     DOI: 10.1053/siny.2002.0108

Source DB:  PubMed          Journal:  Semin Neonatol        ISSN: 1084-2756


  2 in total

1.  Effect of maternal job strain during pregnancy on infant neurodevelopment by gender at 6 and 12 months: Mothers and Children's Environmental Health (MOCEH) study.

Authors:  Eunjeong Kim; HyeSook Park; Yun-Chul Hong; Mina Ha; Yangho Kim; Bo-Eun Lee; Eun-Hee Ha
Journal:  Ann Occup Environ Med       Date:  2015-03-20

2.  Maternal stress in Shank3ex4-9 mice increases pup-directed care and alters brain white matter in male offspring.

Authors:  Bibiana K Y Wong; Jaclyn B Murry; Rajesh Ramakrishnan; Fang He; Alfred Balasa; Gary R Stinnett; Steen E Pedersen; Robia G Pautler; Ignatia B Van den Veyver
Journal:  PLoS One       Date:  2019-11-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.